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IFN-a proteins have been described to originate from14 individual genes and allelic variants. However, the
exceptional diversity of IFN-a and its functional impact are still poorly understood. To characterize the bio-
logical activity of IFN-a subtypes in relation to the cellular background, we investigated the effect of IFN-a
treatment in primary ﬁbroblasts and endothelial cells of vascular or lymphatic origin. The cellular response
was evaluated for 13 distinct IFN-a proteins with respect to transcript regulation of the IFN-stimulated
genes (ISGs) IFIT1, ISG15, CXCL10, CXCL11 and CCL8. The IFN-a proteins displayed a remarkably consistent
potency in gene induction irrespective of target gene and cellular backgroundwhich led to the classiﬁcation
of IFN-a subtypeswith low (IFN-a1), intermediate (IFN-a2a, -4a, -4b, -5, -16, -21) and high (IFN-a2b, -6, -7,
-8, -10, -14) activity. The differential potency of IFN-a classeswas conﬁrmed at the ISGprotein level and the
functional protection of cells against inﬂuenza virus infection. Differences in IFN activity were only
observed at subsaturating levels of IFN-a proteins and did not affect the time course of ISG regulation.
Cell-type speciﬁc responses were apparent for distinct target genes independent of IFN-a subtype and
were based on different levels of basal versus inducible gene expression. While ﬁbroblasts presented with
a high constitutive level of IFIT1, the expression in endothelial cells was strongly induced by IFN-a. In con-
trast, CXCL10 and CXCL11 transcript levels were generally higher in endothelial cells despite a pronounced
induction by IFN-a in ﬁbroblasts.
In summary, the divergent potency of IFN-a proteins and the cell-type speciﬁc regulation of individual
IFN target genes may allow for the ﬁne tuning of cellular responses to pathogen defense.
 2010 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Since interferons (IFNs) were ﬁrst discovered in 1957 [1] a vast
array of familymembers have been identiﬁed. They are divided into
three major classes, the type I, II and III IFNs, which are structurally
related and share distinct properties. While type II and III IFNs are
limited to one (IFN-c) or three (IFN-k) members, the type I IFN fam-
ily includes amultitude of proteins including IFN-a, -b, -e, -j and -x
[2]. Among those, IFN-b, -e, -j and -x are derived from single genes,
whereas IFN-a comprises a remarkable number of subtypes. A total
of 14 human non-allelic IFN-a genes are located on the short arm of
chromosome 9, giving rise to 12 distinct human IFN-a proteins:
IFN-a1, -2, -4, -5, -6, -7, -8, -10, -14, -16, -17 and -21 [3,4]. Overall,
the human IFN-a species show 75–99% amino acid sequence
identity; the protein sequence of IFN-a13 is identical to IFN-a1.urgery, Medical University of
General Hospital 25.05.002,
el.: +43 1 40400 73514; fax:
.at (C. Brostjan).
-NC-ND license.All type I IFNs bind to the same cell surface receptor complex
termed IFNAR which is composed of the two subunits IFNAR1 and
IFNAR2. Ligand binding leads to phosphorylation of the associated
tyrosine kinases and to downstream signaling events. IFN-stimu-
lated gene factor 3 (ISGF3) consisting of STAT1, STAT2 and the IFN
regulatory factor 9 (IRF-9) is activated and binds to IFN-stimulated
response elements (ISREs) to initiate the transcriptional activation
of numerous IFN-stimulated genes (ISGs). The resulting proteins
mediate the biological responses generally attributed to type I IFN,
including anti-viral, anti-proliferative, and immunoregulatory
activities [5,6].
In this context, the diversity of type I interferons has been
debated for many years. Despite the fact that they share a common
receptor, the type I IFN species differ in their potency of anti-viral
and anti-proliferative action [7–10]. Distinct receptor afﬁnity and/
or different interaction sites with the receptor chains have been
proposed to account for the variability in the signals transduced
[11,12]. With respect to cell responses triggered by IFN-b versus
IFN-a, a distinct amino acid composition conserved among the
IFN-a subtypes seems to result in a weaker afﬁnity for IFNAR1
and a generally lower biological activity of the alpha subtypes
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ulation by IFN-b versus IFN-a are only detectable at subsaturating
concentrations, indicating that responses comparable to IFN-bmay
be elicited by high levels of IFN-a [13].
Investigations on the differential activity of the distinct IFN-a
subtypes have generally been limited to a subset of the IFN-a
proteins. A number of studies reported highest and lowest levels
of anti-viral protection for IFN-a8 and IFN-a1, respectively
[7,14]. However, the potency of subtypes seems to vary with the
particular IFN function under investigation [12,15]. Regarding the
signaling events triggered by IFN-a subtypes there are indications
for differential receptor interaction [12,16] and distinct activation
of STAT molecules [9] which may result in divergent ISG regulation
and functional impact of the IFN-a family members.
Furthermore, the context of a given cell type inﬂuences the gene
expression pattern in response to type I IFN [17,18]. For example,
Indraccolo et al. reported the selective induction of ISGs (CXCL10,
CXCL11 and IFIT1) in endothelial cells (ECs) as opposed to primary
ﬁbroblasts after IFN-a/b treatment, indicating that the combina-
tion of cell speciﬁc factors and the type of interferon determine
the ultimate cellular response [19].
Thus, to address the diversity of IFN-a subtypes in the context
of cell-type speciﬁc responses in a comprehensive manner, we
have evaluated cell activation by 13 different IFN-a proteins for
primary endothelial cells and ﬁbroblasts. ISG regulation at the
mRNA and protein level as well as anti-viral activity were investi-
gated in human lymphatic endothelial cells (LECs), in blood vessel
endothelial cells (BECs) and in primary ﬁbroblasts isolated from
the same donor. Based on this detailed analysis we aimed to estab-
lish whether a quantitative and/or qualitative difference in gene
regulation and functional impact can be attributed to the IFN-a
subtypes, in particular for the ISGs previously reported to be differ-
entially induced in endothelial cells and ﬁbroblasts.2. Materials and methods
2.1. Culture and stimulation of primary cells
Primary ECs were isolated from human foreskin samples via
proteolytic digest, and puriﬁed using anti-CD31 antibody coupled
magnetic beads (Invitrogen Corp., Carlsbad, CA). Isolates were cul-
tured in microvascular endothelial growth medium EGM2-MV
(Lonza, Cologne, Germany) containing 1 lg/ml ﬁbronectin, 5%
FCS and human growth factors without the supplementation of
vascular endothelial growth factor (VEGF). For further separation
of LECs and BECs, anti-podoplanin antibody coupled magnetic
beads were applied. Primary ﬁbroblasts were isolated from fore-
skin samples of the same donor via anti-CD90 antibody coupled
beads and cultured in minimal essential medium (Invitrogen) con-
taining 20% FCS and 1 mM sodium pyruvate. All isolates were char-
acterized by ﬂow cytometry for cell-type speciﬁc surface markers,
i.e. CD31, CD34 and E-selectin expression (following TNF-a treat-
ment) for ECs, podoplanin and CD90 expression for LECs and ﬁbro-
blasts, respectively. All cultures showedP95% purity and viability.
Repetitive experiments were conducted with isolates from differ-
ent donors, i.e., represent biological replicates with varying
inducibility.
Forty-eight hours before IFN treatment all primary cells were
seeded in culture dishes supplied with EGM2-MV without VEGF to
reach conﬂuence within 24 h. The medium was then changed to
EGM2-MV without growth factor supplementation. The following
day cells were stimulated with recombinant IFNs diluted in condi-
tionedmediumandcellswereharvestedat the indicated timepoints
for further analysis. All recombinant IFNs applied (PBL Interferon-
Source, Piscataway, NJ) were produced in Escherichia coli andpuriﬁed by ion exchange, hydrophobic interaction and size exclu-
sion chromatography. Furthermore, all subtypes were tested and
certiﬁed to be free of endotoxin (<1 EU/lg).
2.2. Analysis of ISG mRNA expression
RNA was isolated from IFN-stimulated ECs and ﬁbroblasts with
E.Z.N.A. Total RNA Kit (Omega Bio-tek, Inc., Norcross, GA, USA). Sub-
sequently, 250 ng RNA were reverse transcribed with oligo(dT)
primers using the DyNAmo cDNA Synthesis Kit (Finnzymes, Espoo,
Finland) and the generated cDNA was diluted 1:25 for further anal-
ysis. Real-time PCR was performed using either TaqMan probes or
SYBR green incorporation with the respective qPCR MasterMix Plus
Low ROX (Eurogentec, Seraing, Belgium). Primer and probe
sequences are listed in Table 1. Each samplewas assayed in triplicate
with the 7500 Fast PCR Detection System (Applied Biosystems,
Foster City, CA) for 40 cycles of 5 s at 95 C followed by 1 min at
60 C. Transcript levels of target genes were calculated using an
on-plate standarddilution series andwerenormalized to the respec-
tive mRNA levels of the housekeeping genes b-actin (ACTB) and
b2-microglobulin (b2m). The value obtained for the untreated sam-
ple was generally set to 1 to calculate changes in mRNA expression
upon IFN treatment. To compare the amount of target gene tran-
scripts between different cell types, values were normalized to the
same level of housekeeping gene expression in LECs, BECs and ﬁbro-
blasts, andwere subsequently expressed in relation to the untreated
LEC control sample. Statistical analysis was performed using SPSS
10.0.1 Software (SPSS, Inc., Chicago, IL). Student’s T-test was applied
for comparison of mean values; differences between ‘‘potency
categories” of IFN-a subtypes were evaluated by Wilcoxon test.
2.3. Analysis of ISG protein expression
Immunoblotting was performed to determine IFIT1 protein
expression in cytosolic cell extracts. IFN-treated LECs were har-
vested in lysis buffer containing 10 mM HEPES, 10 mM KCl,
0.1 mM EDTA, 1% NP-40 and the Complete Mini Protease Inhibitor
Cocktail (Roche, Indianapolis, IN). After adjusting samples to equal
protein concentration, proteins were separated on 10% polyacryl-
amide/SDS gels and subsequently transferred to polyvinylidene
diﬂuoride membranes (Millipore, Billerica, MA) by semi-dry blot-
ting. Blocking with 5% non-fat milk in PBS with 0.05% Tween20
was followed by immunodetection using a polyclonal a-IFIT1 anti-
body at 1:1000 dilution (Abcam, Cambridge, UK). To test for equal
protein loading a monoclonal a-GAPDH antibody was applied at
1:10,000 dilution (Assay Designs, Ann Arbor, MI). Bound antibody
was detected by peroxidase-conjugated secondary antibody and
the SuperSignal West Femto Detection System (Thermo Fisher
Scientiﬁc, Rockford, IL).
For assessing CXCL10 secretion, LEC culture supernatants were
analyzed by ELISA (Quantikine; R&D Systems, Minneapolis, MN)
according to manufacturer’s instructions. Absorption at 450 nm
was measured with a Wallac Victor3 multilabel counter (Perkin
Elmer Life Sciences, Waltham, MA).
2.4. Analysis of inﬂuenza virus infection and anti-viral IFN activity
Inﬂuenza A virus (PR8) was propagated in Vero cells in serum-
free AIMV medium (Invitrogen) containing trypsin (5 lg/ml). LECs
were pretreated with IFN (100 pg/ml) for 16 h. Cells were then
exposed to the virus for 30 min in serum-free OPTI-PRO medium
(Invitrogen) containing 5 lg/ml trypsin. The MOI (multiplicity of
infection) was set to 1. Subsequently, viral supernatant was
removed and cells were supplied with fresh OPTI-PRO medium.
For the detection of viral protein expression, LECs were
harvested 7 h after inﬂuenza A infection, permeabilized with
Table 1
Sequences of primers and probes applied in real-time PCR analysis.
Gene Primer/probe Sequence
b2m Forward primer 50-CGCTCCGTGGCCTTAGC-30
Reverse primer 50-AATCTTTGGAGTACGCTGGATAGC-30
Probe (Yakima
Yellow/BHQ-1)
50-TGCTCGCGCTACTCTCTCTTTCTGGC-30
ACTB Forward primer 50-CCTGGCACCCAGCACAAT-30
Reverse primer 50-GCCGATCCACACGGAGTACT-30
Probe (6-FAM/
BHQ-1)
50-ATCAAGATCATTGCTCCTCCTGAGCGC-30
IFIT1 Forward primer 50-GATCTCAGAGGAGCCTGGCTAA-30
Reverse primer 50-TGATCATCACCATTTGTACTCATGG-30
Probe (Yakima
Yellow/BHQ-1)
50-CAAAACCCTGCAGAACGGCTGCC-30
ISG15 Forward primer 50-GAGAGGCAGCGAACTCATCT-30
Reverse primer 50-AGGGACACCTGGAATTCGTT-30
Probe (6-FAM/
BHQ-1)
50-TGCCAGTACAGGAGCTTGTG-30
CXCL10 Forward primer 50-CGATTCTGATTTGCTGCCTTAT-30
Reverse primer 50-GGCTTGCAGGAATAATTTCAAGT-30
CXCL11 Forward primer 50-CTTGGCTGTGATATTGTGTGC-30
Reverse primer 50-GGGTACATTATGGAGGCTTTC-30
CCL8 Forward primer 50-AATGTCCCAAGGAAGCTGTG-30
Reverse primer 50-GGGAGGTTGGGGAAAATAAA-30
54 H.P. Moll et al. / Cytokine 53 (2011) 52–59IntraPrep reagent (Beckman Coulter, Inc., Fullerton, CA) and further
stained with a combination of two ﬂuorescence-labeled monoclo-
nal antibodies detecting viral matrix protein as well as nucleopro-
tein (Dako, Glostrup, Denmark). ECs were analyzed for viral protein
expression with an FC500 ﬂow cytometer (Beckman Coulter).
The amount of virus produced by endothelial cells was evalu-
ated 24 h after initial infection, i.e. the virus released into the ser-
um-free supernatant was harvested and subjected to a standard
plaque assay to determine the viral titer as previously described
[20]. Results are given in plaque-forming units per ml (pfu/ml) of
virus supernatant.3. Results
3.1. Induction of ISG mRNA by IFN-a subtypes
Since ISG regulation by type I IFN occurs primarily at the tran-
script level, we ﬁrst investigated ISG mRNA expression in response
to 13 different IFN-a proteins: IFN-a1, -2a, -2b, -4a, -4b, -5, -6, -7,
-8, -10, -14, -16, and -21 (with IFN-a2a and -2b, as well as IFN-a4a
and -4b representing allelic variants of the same gene). Primary
human LECs, BECs and ﬁbroblasts isolated from the same donor
samples were treated with 100 pg/ml of recombinant IFN for 4 h.
Transcript levels of ISGs were determined by quantitative RT-PCR
and mean values of three independent experiments are shown in
Fig. 1 for ﬁve selected genes involved in anti-viral and immunoreg-
ulatory IFN functions (IFIT1, ISG15, CXCL10, CXCL11, CCL8). Data
were calculated as fold induction of ISG mRNA by IFN-stimulation
in relation to the respective untreated control (Fig. 1A–E). Further-
more, we aimed to compare the actual transcript levels present in
LECs, BECs and ﬁbroblasts. Since expression of the housekeeping
genes b2-microglobulin and b-actin did not vary substantially
between the three cell types (data not shown), the ISG values were
normalized to a constant level of housekeeping gene transcripts
(Fig. 1G–K).
The cell-type speciﬁc response to IFN-a was apparent with the
individual target genes rather than the IFN-a subtypes applied;
differences were more distinct between endothelial cells and
ﬁbroblasts than between lymphatic and blood vessel derived ECs.
The basal expression level varied signiﬁcantly for three of the
investigated IFN target genes (Fig. 1L); IFIT1 mRNAwas most abun-dant in ﬁbroblasts whereas highest constitutive expression of
CXCL10 and CXCL11 was found in BECs. Interestingly, the selected
target genes also showed distinct inducibility by IFN-a (irrespec-
tive of subtype) in the three cell types investigated (Fig. 1F). IFIT1
mRNA was highly induced in LECs and in BECs upon IFN-a treat-
ment, whereas fold induction was substantially lower in ﬁbroblasts
(Fig. 1A and F). However, when comparing the transcript levels
present after IFN-stimulation (Fig. 1G) we found that IFIT1 mRNA
was equally abundant in ﬁbroblasts and ECs due to the high level
of basal IFIT1 expression in human skin ﬁbroblasts (Fig. 1L). In con-
trast, ﬁbroblasts showed pronounced induction of CXCL10 and
CXCL11 by IFN-a (Fig. 1C, D and F) but the cellular transcript levels
remained low in comparison to endothelial cells (Fig. 1I and J)
which presented with a higher level of basal expression (Fig. 1L).
ISG15 mRNA concentration was comparable in all three cell types
following IFN-stimulation (Fig. 1H) with LECs showing low base-
line expression (Fig. 1L) but the highest induction values (Fig. 1B
and F). CCL8 induction (Fig. 1E and F) and IFN-induced transcript
levels (Fig. 1K) were distinctly higher in ﬁbroblasts than ECs.
With respect to the induction proﬁle of these ﬁve genes in
response to the various IFN-a subtypes, a recurring pattern of
stimulation was observed, i.e., individual IFN-a proteins showed
consistently high, intermediate or low activity irrespective of
target gene or cellular background. Therefore, we compared the
relative potency of IFN-a subtypes in ISG induction in relation to
IFN-a1 (values set to 1), which generally showed the lowest activ-
ity. The data collected for the ﬁve ISG transcripts were assembled
in a box plot illustration (Fig. 2A) and demonstrated a reproducible
potency of IFN-a subtypes consistent among cell types. Hence, we
further combined the values obtained for the three different cell
types (Fig. 2B) to yield an induction proﬁle for the investigated
IFN-a proteins. Interestingly, three categories of biological activity
emerged, i.e., groups of high, medium and low ISG induction. IFN-
a2b, -6, -7, -8, -10 and -14 were the most potent inducers of ISG
expression with a 4–5-fold higher median level than elicited by
IFN-a1. The subtypes IFN-a2a, -4a, -4b, -5, -16 and -21 displayed
an intermediate capacity to induce ISGs (2–3-fold higher) as
compared to IFN-a1 which consistently gave the lowest induction
values (set to 1). To further substantiate this classiﬁcation, a com-
parison of ISG induction values was performed by Wilcoxon test
and revealed that IFN-a subtypes of the same cluster were signif-
icantly different from all members of the other two ‘‘potency
categories” (p < 0.05 following Bonferroni-Holm correction).3.2. Induction of ISG protein by IFN-a subtypes
To investigate whether the distinct potency of IFN-a subtypes
to induce ISG transcripts was also reﬂected in the amount of
generated protein, a member of each cluster was chosen for subse-
quent experiments: IFN-a1 with low activity, IFN-a4b with inter-
mediate and IFN-a2b with high activity. Since IFN-a subtypes
displayed a consistent induction pattern in all cell types, the inves-
tigations were limited to LECs. After stimulation with recombinant
IFNs, cells were analyzed for mRNA (at 4 or 8 h) as well as protein
expression (at 4, 8 or 24 h).
IFIT1 protein detectable in cytosolic extracts after 8 h of IFN-
stimulation closely correlated with IFIT1 transcript levels (Fig. 3).
While IFN-a2b treatment led to a strong induction of IFIT1 protein,
the expression was substantially lower for IFN-a4b stimulation.
IFN-a1 showed particularly weak induction of IFIT1 protein.
Furthermore, CXCL10 protein levels were evaluated in LEC
supernatant following IFN-stimulation. Protein expression (after
4 h) was in accordance with transcript levels and reﬂected the
ascribed potency of IFN-a subtypes: while IFN-a1 led to minor
CXCL10 secretion, IFN-a4b showed moderate and IFN-a2b high
Fig. 1. ISG mRNA induction and transcript levels upon IFN-a stimulation of LECs, BECs and ﬁbroblasts. Primary cells were stimulated with 100 pg/ml of each IFN-a subtype.
Total RNA was analyzed by quantitative RT-PCR after 4 h of stimulation. The fold induction of IFIT1 (A), ISG15 (B), CXCL10 (C), CXCL11 (D), and CCL8 (E) mRNA was calculated
in relation to the respective untreated control sample of each cell type. Three independent experiments were performed, the mean values of all experiments are given. Due to
high differences in the overall induction values achieved in the three assays (biological variation) the standard deviations are not shown. (F) The mean induction value in
response to all IFN-a subtypes was determined for the ﬁve target genes in the three distinct cell types. Mean and SD are given; signiﬁcant differences (based on Student’s
T-test) in ISG induction between cell types are indicated by one (p < 0.05) or two (p < 0.01) asterisks. (G–L) Since housekeeping gene expression (i.e. transcript level in relation
to total RNA) did not vary substantially between LECs, BECs and ﬁbroblasts (data not shown), ISG values were further normalized to a constant level of housekeeping gene
transcripts to be able to compare ISG mRNA expression between cell types (‘‘relative transcript level”). IFIT1 (G), ISG15 (H), CXCL10 (I), CXCL11 (J), and CCL8 (K) values were
then expressed in relation to the untreated LEC sample (set to 1). (L) To illustrate the variance in basal ISG expression between cell types, ISG transcript levels of untreated
cells were expressed in percent of the highest recorded value. Mean and SD of the three experiments are shown. Differences in basal ISG transcript levels between cell types
were evaluated by Student’s T-test; signiﬁcance levels of p < 0.05 and p < 0.01 are indicated by one and two asterisks, respectively.
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Fig. 2. Relative potency of IFN-a subtypes in ISG stimulation. Induction values for IFIT1, ISG15, CXCL10, CXCL11 and CCL8 were calculated in relation to IFN-a1 levels set to 1.
Data distribution is illustrated by box plot and is given separately for LECs, BECs and ﬁbroblasts (A) or for the combined set of data (B). The deduced classes of high, medium
and low ISG inducers are summarized in (C).
56 H.P. Moll et al. / Cytokine 53 (2011) 52–59stimulatory capacity. CXCL10 protein was stable in EC supernatant
for 24 h.
3.3. Anti-viral activity of IFN-a subtypes
The distinct potency of IFN-a subtypes was further evaluated
with respect to biological function. Since the investigated ISGs
are functionally related to anti-viral defense and immunoregula-
tion, we tested the capacity of IFN-a subtypes to prevent virus rep-
lication. IFN-a1, -2b and -4b were applied in representation of the
established ‘‘potency categories”. After 16 h of pretreatment with
IFN, LECs were infected with inﬂuenza A wildtype virus. The
expression of viral matrix and nucleoprotein was determined in
LECs after 7 h; virus released into the supernatant was detected
at 24 h post infection. The anti-viral activity of the investigated
subtypes correlated with their capacity to regulate ISG mRNA
and protein (Fig. 4). IFN-a1 exhibited the weakest potency to pro-
tect LECs against inﬂuenza infection and propagation whereas
IFN-a4b and IFN-a2b showed intermediate and strong anti-viral
activity, respectively.
3.4. Comparison of time course and dose response to IFN-a subtypes
To establish whether the differences in potency among IFN-a
subtypes could be leveled by increasing the concentration of
available ligand, a dose response experiment was conducted for
the three representatives of IFN-a ‘‘potency categories”. LECs were
treated with increasing concentrations of IFN-a1, -2b and -4b;
mRNA levels of IFIT1 and ISG15 were determined after 4 h. The
maximum level of transcript expression was comparable between
subtypes but was achieved at distinct ligand concentrations
(Fig. 5). The dose required for half-maximal ISG induction was40 pg/ml for IFN-a2b as compared to 200 pg/ml and 400 pg/ml
for IFN-a4b and IFN-a1, respectively.
With respect to potential differences in signal transduction in
response to IFN-a subtypes, the kinetics of ISG mRNA induction
was also investigated (Fig. 6). LECs were exposed to comparable
biological activities of IFN-a proteins as established before, i.e.,
were stimulated with 400 pg/ml IFN-a1, 200 pg/ml IFN-a4b and
40 pg/ml IFN-a2b for 2 to 24 h. IFIT1 transcript levels exhibited a
sharp peak at 4 h post stimulation and were close to baseline after
8 h. An identical time course was observed for the three IFN-a
subtypes applied. ISG15 mRNA peaked at 4 to 8 h; 24 h post
stimulation ISG15 transcript levels were still elevated. The kinetics
of ISG15 mRNA induction was comparable between IFN-a
subtypes.4. Discussion
The exceptional diversity of type I interferons and their func-
tional distinction is an intriguing and largely unanswered question
in the ﬁeld of interferon research. To date 18 human type I IFN
genes have been described, with 14 genes representing the IFN-a
family [2,21]. The IFN proteins produced in response to a pathogen
challenge vary with the particular stimulus and the affected cell
type. Plasmacytoid dendritic cells and peripheral blood mononu-
clear cells are the major sources of IFN-a production, and have
been shown to secrete all subtypes of IFN-a [22,23]. Interestingly,
IFN-a1 has repeatedly been reported to be among the major sub-
types produced [22,24,25].
When we analyzed the potency of 13 different IFN-a proteins in
ISG regulation and anti-viral protection we found a reproducible
pattern of activity in LECs, BECs and ﬁbroblasts, i.e. the subtypes
Fig. 3. Comparison of ISG transcript and protein levels after IFN-a stimulation. LECs were treated with 100 pg/ml of IFN-a1, -2b, or -4b. At the indicated time points, cells and
culture supernatant were harvested. Cell samples were subjected to concomitant mRNA and protein isolation. (A) IFIT1 and CXCL10 mRNA levels were analyzed by real-time
RT-PCR. Data is given as mean and standard deviation of triplicate samples. (B) For analysis of IFIT1 protein expression, cytosolic extracts were subjected to SDS–PAGE and
immunoblotting with anti-IFIT1 antiserum. For loading control, membranes were re-probed with anti-GAPDH antibody. (C) Culture supernatant was analyzed for CXCL10
protein by ELISA.
Fig. 4. Antiviral activity of IFN-a subtypes. LECs were exposed to IFN-a for 16 h or
were left untreated before infection with inﬂuenza A (PR8 wt) virus at an MOI
equaling 1. (A) Cells positive for intracellular expression of viral matrix and
nucleoprotein were determined 7 h post infection by ﬂow cytometry (n = 6). (B) The
amount of virus released into the supernatant 24 h after virus infection was
determined by a standard plaque formation assay (n = 4). Data presented are the
mean and SD of all experiments performed. Differences in anti-viral activity of IFN-
a subtypes were evaluated by Student’s T-test; signiﬁcance levels of p < 0.05 and
p < 0.01 are indicated by one and two asterisks, respectively.
Fig. 5. Dose dependence of ISG regulation by IFN-a subtypes. LECs were treated
with increasing concentrations of IFN-a1, -2b, or -4b for 4 h. Transcript levels of
IFIT1 (A) and ISG15 (B) were analyzed by real-time RT-PCR. Data is given as mean
and standard deviation of triplicate samples.
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types and for the genes investigated. To exclude the possibility of
variation due to incorrect protein concentration we conﬁrmed
the protein content of recombinant IFN preparations by protein
gels (data not shown); minor deviations from the calculated con-
centration did not correlate with the stimulatory potency of IFN-
a proteins.IFN-a1 generally exhibited the weakest activity. Thus, ISG
induction values were set in relation to IFN-a1 and were combined
in statistical analysis of ISG transcript levels. Three categories of
inducers emerged with high (IFN-a2b, -6, -7, -8, -10, -14), interme-
diate (IFN-a2a, -4a, -4b, -5, -16, -21) and weak activity (IFN-a1).
The differential activity of IFN-a subtypes was conﬁrmed at the
protein and functional (anti-viral protection) level for three repre-
sentatives of the ‘‘potency categories”. These results are in line
with previous reports that were focused on a limited number of
IFN-a subtypes. Highest and lowest levels of anti-viral protection
Fig. 6. Kinetics of ISG induction in response to IFN-a subtypes. LECs were exposed
to 400 pg/ml of IFN-a1, 200 pg/ml of IFN-a4b, or 40 pg/ml of IFN-a2b for 2, 4, 6, 8,
12 and 24 h. Induction of IFIT1 (A) and ISG15 (B) mRNA was analyzed by real-time
RT-PCR. Data is given as mean and standard deviation of triplicate samples.
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and IFN-a1, respectively [7,14,26]. It is of interest to note that
the IFN-a subtype with lowest activity is produced at highest
amounts in response to a pathogen challenge which may allow
for a careful adjustment of cellular activation during defense.
With respect to the distinct activity of IFN-a subtypes, it has
been established that the ligands bind to the IFNAR complex with
different afﬁnities. IFN-a1 was described with the lowest afﬁnity
to IFNAR2 [27], an observation coinciding with the weakest activity
of IFN-a1 in our experiments. Furthermore, IFN-a subtypes have
been shown to interact with discrete binding sites on IFNAR2
[12]. These differences may result in divergent signaling events
elicited by IFN-a proteins with respect to STAT activation [9]. How-
ever, we found that a comparable level and time course of ISG
induction is achieved by subtypes of distinct potency (IFN-a1,
-2b, and -4b) when ligand concentrations are increased. Thus,
qualitative and quantitative differences in IFN signals are only
effective at subsaturating levels of IFN-a proteins and may be of
minor importance at local sites of high IFN concentration in inﬂam-
matory reactions.
While the potency of IFN-a subtypes was strikingly consistent
among the three cell types investigated in this study, the selected
target genes (IFIT1, ISG15, CXCL10, CXCL11 and CCL8) displayed a
high degree of cell-type speciﬁc regulation. It should be noted that
LECs, BECs and ﬁbroblasts were isolated from the same donor tis-
sue to minimize the inﬂuence of biological variation. Regarding
the respective function of the selected ISGs, IFIT1 is known to
contribute to anti-viral protection by IFNs [28,29] and ISG15 is
reported to have anti-viral as well as immunoregulatory effects
[30,31]. CCL8, CXCL10 and CXCL11 are chemokines crucially in-
volved in inﬂammatory processes. The selection of ISGs was based
on a previous analysis of genes differentially regulated in endothe-
lial cells and ﬁbroblasts by type I IFN [19]. Indraccolo et al. reported
the preferential expression of CXCL10, CXCL11, and IFIT1 in ECs.
However, these authors did not discriminate between fold induc-
tion and transcript levels. We found that LECs and BECs containedsubstantially higher levels of CXCL10 and CXCL11 mRNA following
stimulation with IFN-a despite a comparable or even higher degree
of gene induction observed in ﬁbroblasts. In contrast, fold
induction of IFIT1 transcripts was noticeably more pronounced in
endothelial cells, but comparable mRNA levels were detectable in
all cell types due to the high basal expression of IFIT1 in ﬁbroblasts.
Thus, the presence of cell-type speciﬁc factors seems to greatly
inﬂuence the scale of ISG expression with respect to the basal
and inducible ISG level. A similar observation has been reported
for the differential expression of CXCL10 in dendritic cells versus
T-lymphocytes [32], indicating that the cell-type speciﬁc regula-
tion of individual IFN target genes may allow for the ﬁne tuning
of cellular responses and contributions to pathogen defense.
Thus, with respect to ISG regulation we have shown that IFN-a
subtypes elicit differential responses at subsaturating levels with
the activity proﬁles being consistent among cell types. Three
categories of high, intermediate and low inducers could be deﬁned.
Differences in ISG expression are further determined by cell-type
speciﬁc factors directing basal and inducible gene regulation.Conﬂict of interest
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